EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery

Zhen-Xin Zeng, Jia-Yi Wu, Jun-Yi Wu, Zhi-Bo Zhang, Kai Wang, Shao-Wu Zhuang, Bin Li, Jian-Yin Zhou, Zhong-Tai Lin, Shu-Qun Li, Yi-Nan Li, Yang-Kai Fu und 1 weitere

Liver Cancer · 27.01.2024 · 13 (5) · 498-508

DOI: 10.1159/000536376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 27.01.2024. Verfasst von Zhen-Xin Zeng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor (triple therapy) has displayed encouraging clinical outcomes for unresectable hepatocellular carcinoma (uHCC). We aimed to explore the prognostic value of pathological response (PR) in patients with initially uHCC who underwent conversion surgery following triple therapy and identify predictors of major pathological response (MPR).

Methods

A total of 76 patients with initially uHCC who underwent conversion surgery following triple therapy were retrospectively analyzed. PR was calculated as the proportion of nonviable tumor cell surface area of the whole tumor bed surface area. MPR was identified when PR was ≥90%. Pathological complete response (pCR) was defined as the absence of viable tumor cells.

Results

MPR and pCR were identified in 53 (69.7%) and 25 (32.9%) patients, respectively. The 1- and 2-year overall survival in patients with MPR were significantly higher than in those without MPR (100.0% and 91.3% vs. 67.7% and 19.4%; p < 0.001). The corresponding recurrence-free survival was also improved in patients with MPR compared to those without (75.9% and 50.8% vs. 22.3% and 11.2%; p < 0.001). Similar results were observed among patients with pCR and those without. Patients who achieved MPR without pCR exhibited survival rates comparable to those of patients who achieved pCR. Baseline neutrophil-to-lymphocyte ratio ≥2.6 (p = 0.016) and preoperative alpha-fetoprotein level ≥400 ng/mL (p = 0.015) were independent predictors of MPR.

Conclusion

The presence of MPR or pCR could improve prognosis in patients with initially uHCC who underwent conversion surgery following triple therapy. The PR may become a surrogate marker for predicting the prognosis of these patients.

Schlagwörter

Stichwörter der Autor:innen

Conversion surgeryHepatocellular carcinomaOverall survivalPathological responsePredictive factorRecurrence-free survival

Autor:innen und Institutionen

  • Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
  • Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, China.
  • Department of Hepatopancreatobiliary Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Department of Interventional Radiology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China.
  • Department of Hepato-Biliary-Pancreatic and Vascular Surgery, First Affiliated Hospital of Xiamen University, Xiamen, China.

Zitieren

APA

Zeng, Z. X., Wu, J. Y., Wu, J. Y., Zhang, Z. B., Wang, K., Zhuang, S. W., Li, B., Zhou, J. Y., Lin, Z. T., Li, S. Q., Li, Y. N., Fu, Y. K., & Yan, M. L. (2024). Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery. Liver Cancer, 13(5), 498-508. https://doi.org/10.1159/000536376

Vancouver

Zeng ZX, Wu JY, Wu JY, Zhang ZB, Wang K, Zhuang SW, et al. Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery. Liver Cancer. 2024;13(5):498-508. doi:10.1159/000536376

BibTeX
@article{Zeng2024,
  author = {Zeng, Zhen-Xin and Wu, Jia-Yi and Wu, Jun-Yi and Zhang, Zhi-Bo and Wang, Kai and Zhuang, Shao-Wu and Li, Bin and Zhou, Jian-Yin and Lin, Zhong-Tai and Li, Shu-Qun and Li, Yi-Nan and Fu, Yang-Kai and Yan, Mao-Lin},
  title = {Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery},
  journal = {Liver Cancer},
  year = {2024},
  volume = {13},
  number = {5},
  pages = {498--508},
  doi = {10.1159/000536376}
}
Kostenlos starten →